Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nanoparticles encapsulating TLR7 agonist 1v270 MBS8

A micelle nanoparticle formulation composed of the Toll-Like receptor 7 (TLR7) agonist phospholipid conjugate 1v270 encapsulated within 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-polyethylene glycol (PEG)-2000, with potential immunostimulating activity. Upon intravenous administration of the nanoparticles encapsulating TLR7 agonist 1v270 MBS8, the TLR7 agonist targets, binds to and activates TLR7, thereby stimulating dendritic cells (DCs) and neutrophils, and enhancing natural killer cell (NK) cytotoxicity. This activation results in the production of pro-inflammatory cytokines, including interferon alpha. MBS8 may activate cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses leading to tumor cell lysis. In addition, MBS8 is able to stimulate immune memory T cells to further recognize and eliminate cancer cells. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and the activation of innate immunity. The micelle formulation was engineered to reduce systemic cytokine production which may lower systemic toxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DOPE-PEG2000/1v270 micelles MBS8
TLR7 agonist 1v270-containing micelles MBS8
Code name:MBS 8
MBS-8
MBS8
MBS8(1V270)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search